1. CONFIDENTIAL Michael Nagel, President and CEO

2. How Is New Technology Viewed? “Gee Whiz” has become “So What?”

3. The OLD Sales Model & Conversation Patien t Physician Gatekeeper The Story: Technology Features, Benefits, Advantages Hospital Sales Rep

4. A New Sales Model & Conversation Gatekeepers GP O IDN GOVT Hospital Outpatient Facility Long Term Care Facility The Story: Cost-benefit, Economic Feasibility, Risk Sharing, ‘Added Value’ Patien t Physician Sales Rep Corp Accts

6. Elemental Silver Imbedded in the dressing are wireless microcell batteries Elemental Zinc In the presence of a conductive fluid (i.e. saline, hydrogel, wound exudate) batteries are activated and generate microcurrents at the dressing surface Procellera Technology is the first of its kind microcurrent generating antimicrobial wound dressing

7. Today’s Environment … More capital investment required More time – less room for errors More evidence required More decision makers Less investment capital available … calls for a different approach

8. What Builds Value For Stakeholders? Potential market size Clinical value Patents Margins Share of market AND economic viability of technology

9. Funding Infrastructure Technology Evidence Strategic Plans Tactical Execution Strategic Plans Tactical Execution Top / Bottom Line Growth Key hires and abilities needed at this stage Today’s Strategic Outlook Studies must aim at demonstrating BOTH clinical and economic value Partnerships may be KEY to future technologies

10. 10 Scientific & Clinical Evidence Inspired by the body. Powered by electricity. Energized by results.

11. Research Collaborators 11

12. Broad Scientific and Clinical Interest GROWING BODY OF EVIDENCE 7 Publications & 49 Peer Reviewed Abstracts

13. NOTE: Multicenter retrospective study; N=38 (SOC n=20, Procellera n=18) Acute & chronic, partial & full- thickness wounds Whitcomb E, Monroe N, Hope-Higman J, Campbell P. Demonstration of a Microcurrent-Generating Wound Care Device for Wound Healing within a Rehabilitation Center Patient Population. Journal of the American College of Clinical Wound Specialists 2013; 4(2):32-39. Day 0 Week 3 13 Reduced Healing Time RETROSPECTIVE CLINICAL STUDY

14. St. Luke’s Medical Center Total Knee Arthroplasty, Retrospective; N=100 Findings: Reduced LOS, readmission and infection rates vs. published literature Clinical & Cost Efficacy Studies with Procellera Reduced LOS 3.5 Days 2.4 Days Reduced Infection & Readmission Rates Tribal Healthcare Facility Acute /chronic wounds, retrospective; N=18 Findings: Reduced cost/cm2 to heal vs. skin substitutes, NPWT; 47% reduced time to heal Chow et al, Orthopedics 2014. Manuscript in submission.Yamada et al, SAWC 2014

15. Clinical & Cost Efficacy of Procellera + NPWT Acute surgical wounds, prospective, N=30 Interim Findings: 22% cost savings in NPWT costs and 33% cost savings in narcotic analgesic costs, vs. NPWT alone Reduced healing times and reduced dressing changes Reduced CostImproved Closure Rates vs. NPWT alone Barki, Das, Schlanger et al. Bioelectric Dressing Reduces Cost of Care for Ipatients with Acute Surgical Wounds Treated with NPWT. In: 7 th Annual Translational to Clinical Regenerative Medicine Wound Care Conference, Columbus, OH. March 2014. # of Participants

16. August 1, 2014 GPO Contract Status

17. New Model For Winning Teams Diverse strengths and backgrounds – no duplicity Wide use of consultants – best in class Engaged employees that connect to the mission Flexibility and speed to market

18. New Model for Device Companies Companies must operate leaner Substance over “fluff” Studies must be well designed and strategy carefully thought out Clear line of sight to core competencies Rethink traditional sales models Service (‘value-add’) takes on new importance Partnership considerations